Progress on the cardiotoxicity of sunitinib: Prognostic significance, mechanism and protective therapies
Authors:
- 1 September 2016
- journal article
- review article
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 257, 125-131
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81070076, 81170135)
- National 973 Basic Research Program of China (2012CB722406)
This publication has 70 references indexed in Scilit:
- Coronary Microvascular Pericytes Are the Cellular Target of Sunitinib Malate–Induced CardiotoxicityScience Translational Medicine, 2013
- Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic CardiomyopathyCirculation, 2010
- Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stressJournal of Clinical Investigation, 2010
- Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancerBritish Journal of Cancer, 2009
- Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein KinaseClinical and Translational Science, 2009
- Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart FailureCirculation Research, 2009
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokinesJournal of Clinical Investigation, 2006
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001